- Home
- NEWT vs MRVI Comparison
NEWT vs MRVI Comparison
Compare NEWT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- MRVI
- Stock Information
- Founded
- NEWT 1998
- MRVI 2014
- Country
- NEWT United States
- MRVI United States
- Employees
- NEWT N/A
- MRVI 560
- Industry
- NEWT Major Banks
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- MRVI Health Care
- Exchange
- NEWT Nasdaq
- MRVI Nasdaq
- Market Cap
- NEWT 294.8M
- MRVI 350.1M
- IPO Year
- NEWT N/A
- MRVI 2020
- Fundamental
- Price
- NEWT $12.37
- MRVI $2.42
- Analyst Decision
- NEWT Hold
- MRVI Hold
- Analyst Count
- NEWT 4
- MRVI 10
- Target Price
- NEWT $13.00
- MRVI $5.84
- AVG Volume (30 Days)
- NEWT 188.9K
- MRVI 1.5M
- Earning Date
- NEWT 07-28-2025
- MRVI 08-11-2025
- Dividend Yield
- NEWT 6.14%
- MRVI N/A
- EPS Growth
- NEWT 21.23
- MRVI N/A
- EPS
- NEWT 2.01
- MRVI N/A
- Revenue
- NEWT $364,004,000.00
- MRVI $219,830,000.00
- Revenue This Year
- NEWT N/A
- MRVI N/A
- Revenue Next Year
- NEWT $12.73
- MRVI $7.23
- P/E Ratio
- NEWT $6.15
- MRVI N/A
- Revenue Growth
- NEWT 20.91
- MRVI N/A
- 52 Week Low
- NEWT $9.12
- MRVI $1.67
- 52 Week High
- NEWT $15.49
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- NEWT 61.20
- MRVI 49.60
- Support Level
- NEWT $12.16
- MRVI $2.28
- Resistance Level
- NEWT $12.48
- MRVI $2.47
- Average True Range (ATR)
- NEWT 0.27
- MRVI 0.14
- MACD
- NEWT 0.02
- MRVI -0.01
- Stochastic Oscillator
- NEWT 73.00
- MRVI 27.45
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.